• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

Technologies.org

Technology Trends: Follow the Money

  • Sponsored Post
    • Make a Contribution
    • Technology Job Posting
  • Technology Events 2022-2023
  • Technology Domains
  • Technology Markets
  • Venture Capital
  • Contact
    • About

Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing

June 7, 2022 By Technologies.org Leave a Comment

Up-round financing follows a previously unannounced $600 million Series C Financing completed in August 2021

SAN DIEGO, June 06, 2022 – National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced it has raised $625 million in a Series D financing, in addition to a previously unannounced $600 million Series C financing completed in August 2021.

The company will use the funding to continue to invest in building its infrastructure network through strategic collaborations, acquisitions, organic growth and international expansion, and by developing innovative biomanufacturing technologies to ensure the medicines of today and tomorrow can be made quickly, safely and at scale. Resilience is also investing in advanced R&D, including stable cell lines for viral vector production, distributed manufacturing for autologous cell therapy and cell-free and continuous manufacturing for biologics.

“We have an ambitious goal to reinvent biomanufacturing by bringing new processes and technologies to an industry that hasn’t kept pace with the explosive innovation in drug discovery,” said Rahul Singhvi, Sc.D., Chief Executive Officer of Resilience. “While we recognize that our goal is neither quick nor easy, we are driven by our mission to democratize access to medicines. These new funds will help support our next phase of growth, as we continue to innovate biomanufacturing across all our modalities, expand our footprint to serve customers, sign strategic collaborations and support the developers of a new generation of complex medicines.”

Resilience, which focuses on five therapeutic modalities – biologics, vaccines, nucleic acids and cell and gene therapies – currently has 10 facilities across North America, with more than 1 million square feet of manufacturing space and more than 1,600 employees. The company’s network, which is expected to add capacity and capabilities this year with projects underway at several existing sites, is agile enough to scale customer projects from process and analytical development through preclinical to large scale commercial drug substance and drug product manufacturing.

Resilience‘s flexible business model enables it to partner with customers of any size and across therapeutic modalities, through fee-for-service arrangements, value-share agreements and new company creation/incubation projects. The company also provides opportunities for early access and out licensing of next-generation technologies. Beyond industry customers and partners, Resilience works with government agencies, academic institutions and non-profit organizations.

The latest up-round financing was led by new and existing investors, including venture capital funds, public mutual funds, pension funds, biopharma companies, sovereign wealth funds and private family offices, among others. In total, Resilience has secured more than $2 billion in equity financing since its founding in 2020.

Recent Notable Milestones and Developments

Technology:

Acquired SwiftScale Biologics, a company developing cell-free protein synthesis, a technology that aims to eliminate the constraints of using living cells in the drug manufacturing process, resulting in faster production times, less variability across batches and greater scalability with hard-to-produce proteins.
Customers:

Established a multi-product development and manufacturing collaboration with Takeda’s Plasma-Derived Therapies Business Unit.
Secured a contract with the U.S. Department of Defense for manufacturing a monoclonal antibody as a medical countermeasure to botulinum neurotoxins.
Signed a strategic manufacturing services agreement with Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases.
Manufacturing Infrastructure:

Acquired bluebird bio’s Research Triangle manufacturing facility in North Carolina.
Added capacity and capabilities including drug substance and drug product manufacturing expansions coming online in 2022 across sites in Alachua, FL, Boston and Toronto, to support biologics and vaccines.
Constructing a new, state-of-the-art facility in Marlborough, MA to support vaccines and gene therapy, coming online in 2023.
Adding a new cell and gene therapy process and analytical development as well as drug substance manufacturing site in the Philadelphia region.
Academic Collaborations & Incubations:

Launched a joint venture with The University of Texas MD Anderson Cancer Center to accelerate the development and manufacturing of innovative cell therapies for patients with cancer.
Entered into a five-year R&D alliance with Harvard University to incubate new technologies and launch companies to advance the manufacture of complex medicines.
Formed a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement next-generation biomanufacturing technologies and capabilities aimed at accelerating the creation of impactful therapies and technologies for the benefit of patients.
Value-Share Agreements:

Formed a strategic collaboration with Be Biopharma to manufacture engineered B Cells to create a new class of autologous and allogeneic cellular medicines.
About Resilience

Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the medicines of today and tomorrow can be made quickly, safely and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives.

For more information, visit www.Resilience.com and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.

Related

Filed Under: Tech

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

Market Research

BigTechMatters.com: Big Tech Matters
OpInt.com (Operational Intelligence): Tailored project delivery intelligence reduces risk
ASAPtakeaways.com: ASAP Takeaways have become a global market worth more than $150 billion
VisualMediaMarket.com: Visual Media Market
GruyereCheese.ch: Gruyere Cheese is Swiss
Decoy Networks: “decoys become your only way of hiding”
Revenues in the entertainment and media industry are on the rise globally

Market Analysis

Comparing WordPress Performance on MySQL vs SQLite
E-commerce pure play doesn’t require the heavy outsourcing
Global Derivatives Regulatory Roundup
The Pentagon’s FY2023 budget request for hypersonic-related research is $4.7 billion
Portuguese wine market is booming
Wearable IoTs
The future of global healthcare in 2022

Tech Events

Fira de Barcelona celebrates the extension of MWC Barcelona until 2030
Jamstack Conf 2022, November 7-8 2022, San Francisco and online
Photonics Industry Summit, September 21, 2022, Washington, DC

Secondary Sidebar

Venture Capital

Penny AI Raises $27 Million Series B to Accelerate the Transformation of Social Commerce Enablement Platforms
Danish CleanTech ZeroNorth Raises Over $50 Million Series B Round to Help Decarbonise Shipping
Turing Achieves Unicorn Status Following Series D Bringing Total Raised to Over $140 Million
Palm NFT Studio Announces $27M Series B Funding
Taptap Send raises $65M to build cross-border remittances
Houwzer Raises $118M In Series B Equity and Debt To Expand Within Seven-State Footprint, Launches Three New Consumer Products To Give Clients Competitive Edge
The World’s Biggest Startups: Top Unicorns of 2021
Blockchain co Starkware raises $100m at $8b valuation
Europe’s Only Deeptech Demo Day: Deeptech Labs’ Unveil 6 New Accelerator Start-ups
Inovia Closes US$325 Million Early-Stage Fund

Footer

Recent Posts

  • Ceres and Shell announce electrolyser agreement for green hydrogen
  • Datadog Launches Audit Trail to Help Businesses Achieve Their Compliance and Governance Objectives
  • Samsung Unveils ISOCELL Image Sensor with Industry’s Smallest 0.56μm Pixel
  • Box Launches Technology Collaboration with FUJIFILM Business Innovation
  • VivaTech, Europe’s number one startup and tech event, makes its big comeback with more than 91,000 participants in Paris
  • Cloudflare Expands Its Zero Trust Platform to Become the Only Cloud-Native Provider with Network Scale
  • New Zealand’s leading port, Ports of Auckland, welcome the world’s first full sized, electric tugboat
  • Energy Dome Successfully Launches First CO2 Battery Long-Duration Energy Storage Plant in the World
  • Resilience Announces $625 Million Series D Financing to Expand Network, Bring Innovative Technologies to Biomanufacturing
  • Apple Unveils M2, Taking the Breakthrough Performance and Capabilities of M1 Even Further

Media Partners

  • VPNW
  • S3H
  • OPINT
  • Press Media Release
  • OSINT
  • Digital Market
  • Briefly

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Opinion
  • Venture Capital

Copyright © 2015 Technologies.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT